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Background: Adverse drug events (ADEs) are frequent in hospitals, occurring either in patients before admission or
as a nosocomial event, and either as a drug reaction or as a consequence of a medication error. Routine data
primarily recorded for reimbursement purposes are increasingly being used on a national level both in
pharmacoepidemiological studies and in trigger tools. The aim of this study was to compare the prevalence rates
of coded ADEs in hospitals on a transnational level.
Methods: Hospital data for England and the USA were obtained for the fiscal or calendar year 2006. German data
for 2006 were accessed via teleprocessing with the Federal Statistical Office. The datasets from England and the
USA were adapted to the German data. About 6 million (England), 7 million (USA), and 16 million (Germany)
inpatients could be included. ADEs were identified through a list of codes used in the national diagnosis
classifications.
Results: The overall prevalence rate (and 95% confidence interval, CI) of coded ADEs was 3.22% (3.20–3.23%) for
England, 4.78% (4.73–4.83%) for Germany, and 5.64% (5.63–5.66%) for the USA. Most of the English ADE cases
occurred in patients admitted as emergency. A non-surgical status and a longer length of stay were consistently
associated with the occurrence of an ADE. Enterocolitis caused by Clostridium difficile was the most frequent ADE
in all countries.
Conclusions: According to routine data, the overall ADE prevalence rates for England, Germany, and the USA are
different. However, the differences are narrower than those determined from the rates of ADEs or adverse drug
reactions inferred from prospective or retrospective pharmacoepidemiological studies. Since the ADEs in the
countries examined in this study share several characteristics, the use of routine data for transnational research on
ADEs is feasible.
Keywords: Adverse drug event, Adverse drug reaction reporting system, Hospitals, International classification of
diseases, Medication errors, Routine dataBackground
Adverse drug events (ADEs) can be defined as “harm
caused by the use of a drug” [1], which implies that they
are identifiable through their associated symptoms and
diseases. Therefore, upon initial consideration, the cod-
ing of ADEs using the International Classification of
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reproduction in any medium, provided the orpossible, because the ICD thoroughly covers diseases
and symptoms. However, it is also possible that coding
circumstances and standards hamper the use of ICD
codes for ADEs [2]. Nonetheless, there is a growing body
of literature on pharmacovigilance employing ICD-
coded diseases and symptoms [3-5]. The codes could
also be used in the timely detection of ADEs, especially
when evaluated in combination with other information
such as lab values in trigger tools [6].
However, the definition of an ADE as “harm caused by
the use of a drug” [1] excludes a few relevant issues relatedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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do not cause harm are excluded, as are near-miss events.
Those situations do not interfere with the use of ICD
codes because they do not lead to symptoms or diseases.
On the other hand, an unintended low dose or a missing
prescription of a drug could cause harm related to the in-
appropriate treatment of a patient’s condition. In such
cases, ICD codes might indicate the harm as ongoing or
as a deteriorating pathological state of the patient. The
complex and manifold settings considered in patient safety
and pharmacovigilance are reflected in the diversity of
terms and definitions used to describe them [7].
ADEs are a burden on healthcare systems because of
the resources needed to diagnose and treat the symptoms
and diseases caused by them. From the perspective of so-
ciety, these costs are unnecessary, regardless of the point
of origin. Thus, ADEs present on admission and nosoco-
mial ADEs should be grouped together to estimate the
cost of ADEs in inpatients. A microcosting study in
Germany used routine data to extrapolate the annual total
costs, reporting a price tag of about 1 billion Euros [8].
This amount is in line with the one published for prevent-
able ADEs in the USA, around 2 billion USD [9].
It seems reasonable to estimate the burden of ADEs
arising from the inpatient sector by using routine data to
calculate the frequencies of ICD-coded diagnoses. Rou-
tine data are generated because of regulations in reim-
bursement systems that apply diagnosis-related groups
(DRGs) and they are available at low cost in many devel-
oped countries. A report of the Organisation for Eco-
nomic Co-operation and Development (OECD) uses
such data to compare the rates of the Agency for
Healthcare Research and Quality (AHRQ) Patient Safety
Indicators, provided by participating countries to enable
a transnational comparison [10]. For example, 19 coun-
tries contributed data for the indicator “Foreign Body
Left During Procedure”. All but three of those countries
apply DRGs for reimbursement, and all but one apply
the ICD system for the coding of diagnoses. Thus, it
should also be possible to use routine data for a trans-
national comparison of ADEs. In the following, we
present the results of a study on the frequency of ADEs
in England, Germany, and the USA. These countries
were chosen because of the availability of data and/or
the existence of previous relevant publications. The aims
of this study were to elaborate the feasibility of trans-
national comparisons using routine data and, by apply-
ing the same approach, to compare routine-data-based
ADE rates between different countries.
Methods
Definitions
In this study, an ADE was defined as an injury resulting
from a medical intervention related to a drug and thusincluded both adverse drug reactions (ADRs) and the
consequences of medication errors [11]. ADEs related to
the omission of a medication or to a medication dose
that was too low were not explicitly covered by this def-
inition. ADEs present at the time of admission and those
occurring during a hospital stay were both considered.
Accordingly, the results reflect hospitals’ burdens of ADEs
independent of the question of responsibility. In the inter-
national literature in which ICD codes were applied in the
identification of ADEs, the terms ADR and ADE are used
inconsistently [7]. Since many ICD codes do not precisely
distinguish between ADRs and the consequences of medi-
cation errors, the term ADE is preferably used throughout
this paper.
Datasets
The National Health Service Information Centre for
Health and Social Care (NHS Information Centre) offers
datasets for the different sectors of the English health care
system. The Hospital Episode Statistics (HES) includes all
inpatients served by “acute hospitals, primary care trusts
and mental health trusts” [12]. It covers a financial year
extending from April to March, with data available for
every financial year from 1989/1990 onwards. HES data
are collected monthly. The observational unit is the epi-
sode, defined as the period of time that a patient is under
the care of one consultant. Episodes can be aggregated to
describe either an inpatient stay or a particular patient by
using different identifiers or service-related data elements.
Diagnoses are coded using the ICD-10, and procedures by
a national procedure classification. A maximum of 20
diagnosis codes and 24 procedure codes are allowed per
episode. We obtained the raw data for the financial year
2006/2007 (1st April 2006 to 31st March 2007). These raw
data were representative of 15,804,643 episodes. Inpatients
admitted before or discharged after the financial year were
included as long as there was at least one episode that
overlapped with that financial year.
The AHRQ maintains the National Inpatient Sample
(NIS) as part of the Healthcare Cost and Utilization
Project [13]. The NIS has been available yearly since
1988. Information on inpatient stays consists of clinical
and resource use aspects, available from discharge ab-
stracts. The NIS draws information from the 20% of hos-
pitals in the USA that are stratified for region, location,
teaching status, bed size, and ownership. The inclusion of
hospitals, inpatient stays, and data elements varies in the
different states. The documentation notes state-specific
restrictions arising from confidentiality agreements related
to hospitals, records, physicians, and discharges (for ex-
ample, patients with HIV infections). The observational
unit is the inpatient stay. Patient identifiers are not avail-
able. Diagnoses and procedures are coded with the ICD-9
Clinical Modification (ICD-9-CM). A maximum of 15
Table 1 Number of codes indicating an adverse drug










A Caused by a drug or
other substance
122 179 275
A.1 Caused by a drug 44 101 184
A.2 Caused by a drug or
other substance
78 78 91
B Poisoning by or
harmful use of a drug
or other substance
189 148 232
B.1 Poisoning by drug 133 133 195
B.2 Poisoning by or
harmful use of a drug
or other substance
56 15 37
C ADE very likely 27 30 18
A-C 338 357 525
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inpatient stay. ICD-9-CM codes for external causes of in-
jury and poisoning are stored separately. A maximum of
four of those codes are allowed per inpatient stay. For this
study, raw data for the calendar year 2006 were obtained
from the AHRQ. These data were derived from 8,074,825
inpatients from 1,045 hospitals. The inpatients were ad-
mitted in 2006 or earlier and discharged in 2006.
Since 2002, German hospitals have been obligated to an-
nually deliver a standard data set to the Institute for the
Hospital Remuneration System (InEK). The data consist
of information on all inpatients covered by the DRG sys-
tem. Some of the aggregated data are published by the
InEK for use in ecological studies. The data can further be
used as a DRG statistic through teleprocessing at the
Federal Statistical Office. In teleprocessing, a customer
sends a script for a statistical software package to the
Federal Statistical Office. The script is then executed by its
staff and the resulting report is sent back to the customer.
The observational unit in the DRG statistic is the inpatient
stay. Data are available starting with the year 2005. No pa-
tient identifier is available. Diagnoses are coded with the
ICD-10 German Modification (ICD-10-GM), and proce-
dures with a national procedure classification. A maximum
of 90 diagnosis codes and 101 procedure codes are allowed
per inpatient stay. The inpatients included in this study
were admitted in 2006 or earlier and discharged in 2006.
The results are based either on the InEK data or on the
DRG statistic for the calendar year 2006, both of which
were published previously [14,15].
Identification of the relevant ICD codes
A list of 502 ICD-10-GM codes indicating a possible ADE
was previously developed [5]. The identified codes were
classified into seven categories based on the validity of
each one as an indicator of an ADE and its definition in
the ICD-10:
 A.1: A drug-related causation was noted in the
ICD-10, e.g., G44.4 “Drug-induced headache, not
elsewhere classified”.
 A.2: A drug- or other substance-related causation was
noted in the ICD-10, e.g., I42.7 “Cardiomyopathy
due to drugs and other external agents”.
 B.1: The event was denoted as a drug poisoning,
implying a non-physiological dosage, e.g., T36.0
“Poisoning: Penicillins”.
 B.2: The event was denoted as poisoning by or
harmful use of a drug or other substance,
e.g., T50.9 “Poisoning: Other and unspecified
drugs, medicaments, and biological substances”.
 C: A drug-related causation was very likely,
e.g., A04.7 “Enterocolitis due to Clostridium
difficile”. D: A drug-related causation was likely, e.g., F52.2
“Failure of genital response”.
 E: A drug-related causation was possible, e.g., J81
“Pulmonary edema”.
Categories C, D, and E were distinguished through
expert opinion [5]. The study only considered codes of
categories A, B, and C, as they are the ones that very
likely take into account the administration of a drug. For
categories A.2 and B.2, however, other substances or
measures may also have caused the event.
Mapping process
The list of 502 ICD-10-GM codes indicating a possible
ADE was mapped onto the ICD-10 NHS and the ICD-
9-CM. Table 1 shows the result of the mapping process.
For ICD-10 NHS mapping, a license was obtained from
the WHO for the UK version of the ICD-10. Included with
that license was a file from the NHS containing metadata
of the ICD-10 NHS. After direct mapping from the ICD-
10-GM to find the ADE codes in the ICD-10 NHS, the fol-
lowing aspects were determined: a) whether the resulting
ICD-10 NHS codes truly indicated an ADE and b) whether
the category of the resulting code was the same as the cat-
egory from the starting code of the German ICD-10-GM.
If necessary, the results were adapted accordingly. Further-
more, for those ADE codes of the German ICD-10-GM
without a hit in the ICD-10 NHS, an appropriate mapping
was determined manually, by browsing the list of codes in
the ICD-10 NHS metadata. Open questions were resolved
by a consensus reached by a group of two persons.
Documents for the ICD-9-CM were downloaded
from the web page of the Centers for Disease Control
and Prevention (cf. http://www.cdc.gov/nchs/icd/icd9cm.
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the different mapping tables: ICD-10-GM 2006 onto ICD-
10 SGB-V 2.0 (an earlier German version of ICD-10) onto
ICD-10 SGB-V 1.3 (an earlier German version of ICD-10)
onto the German version of the ICD-9 WHO V6.0. The
resulting ICD-9 WHO codes were then directly mapped
onto the ICD-9-CM. Furthermore, the document of the
ICD-9-CM, in rich text format (RTF), was manually
checked for ADE codes using terms such as “drug”. The
same aspects as described above for the mapping of ICD-
10-GM onto ICD-10 NHS were determined and, as neces-
sary, the results were adapted accordingly. Furthermore,
for those ADE codes of the German ICD-10-GM without
a hit in the ICD-9-CM, an appropriate mapping was de-
termined, by browsing the RTF document. Open ques-
tions were resolved as described above.Data pre-processing
The data were cleaned to generate datasets comparable
with the German DRG statistic, at least regarding basic
plausibility checks. For the HES, episodes were aggregated
to inpatient stays using the hospital provider spell number,
sex, date of admission, method of admission, source of ad-
mission, and end of inpatient stay. Excluded were inpa-
tients for whom data on age, sex, method of admission,
destination after discharge, method of discharge, principal
diagnosis, admission date, discharge date, or length of stay
were missing or invalid. Also excluded were data from in-
patients admitted before or discharged after the financial
year, as well as duplicates. Thus, a total of 13,547,900 in-
patient stays were included. For more than 7 million of
them, a length of stay of null days was recorded. These in-
patient stays were then excluded, based on the assumption
that they were administratively recorded but not person-
ally served by the hospitals. That kind of stay was not
present in the datasets from Germany and the USA. Fi-
nally, 6,202,313 inpatient stays were considered (44.0%
from the HES).
From the NIS inpatient stays were excluded in which
data on sex, admission type, disposition of patient (dis-
charge status), principal diagnosis, and length of stay were
missing. Further excluded were data from inpatients ad-
mitted before 2006. The final number of inpatient stays
considered was 7,125,028 (88.2% from the NIS).
Inpatients who underwent surgery were defined in the
case of England by the value “one or more operative
procedures carried out” as operation status code; in the
case of Germany by at least one procedure code from
the chapter "operation" of the national procedure classi-
fication; and in the case of the USA by at least one pro-
cedure code from those parts of the ICD-9-CM related
to surgical interventions. All other cases were treated as
not including an operation.Statistics
ADEs were identified using both the principal and the sec-
ondary diagnoses. If more than one ADE was identified for
an individual inpatient stay, that stay was counted only
once. The data were managed with MySQL 5.x (Oracle
Corporation) and Microsoft Access 2007/2010. For ana-
lysis, Microsoft Excel 2007/2010 and SAS 9.2 (SAS Insti-
tute Inc.) were used. ADE rates were calculated by dividing
the number of inpatient stays in which there was at least
one ADE by the total number of inpatient stays. The rates
are reported as percentages, with the 95% confidence inter-
val (CI) in square brackets. Given the results available with
the DRG statistic, the rates from England and the USA
were adjusted for the distribution of the following data ele-
ments in the DRG statistic using a direct standardization:
operation (yes/no), sex (male/female), emergency (yes/no),
age at admission (≤ 53 years/>53 years). The mean age at
admission for German inpatients was chosen as the
threshold value for the age at admission. To correct for
differences in coding completeness, the rates for each
country were multiplied by the result of the “mean num-
ber of secondary diagnoses in Germany” divided by the
“mean number of secondary diagnoses in this country”,
yielding 1.71 for the HES, 1.00 for the DRG statistic, and
0.74 for the NIS.
To corrects for shifts of codes between subcategories
occurring after the mapping, categories A.1 and A.2
were combined to form category A, and categories B.1
and B.2 to form category B. Inpatient stays were counted
once within each remaining category (A, B, and C) for
England and the USA. For Germany, inpatients stays
were counted twice in categories A and B if an ADE oc-
curred in each respective sub-category. Otherwise, they
were counted once for the remaining categories (A, B,
and C), as for England and the USA. Furthermore, the
results for Germany were initially split into principal and
secondary diagnoses. Among the patients in whom ADE
was the principal diagnosis, 12% also had an ADE as the
secondary diagnosis (unpublished results). To adjust for
this overlap, the German prevalence rates for categories
A, B, and C were multiplied by a factor of 0.88.
The odd ratios with their 95% CIs were calculated for
operation status, sex, emergency status, age at admission,
and length of stay (≤ 10 days/> 10 days). The five most fre-
quent ADEs in each country are reported.
Due to the use of anonymized data in this study, the
approval of an ethics committee was not necessary.
Results
Study populations
Table 2 shows the characteristics of the three study pop-
ulations. Among the German population, there were
fewer women (53.8%), fewer emergency cases (35.1%),
and fewer operations (40.4%) than in the populations




Total (%) 6,202,313 (100.0) 16,230,407 (100.0) 7,125,028 (100.0)
Male (%) 2,677,383 (43.2) 7,505,172 (46.2) 2,957,623 (41.5)
Emergency (%) 3,361,405 (54.2) 5,702,142 (35.1) 3,252,330 (45.7)
Operation (%) 2,836,784 (45.7) 6,563,549 (40.4) 3,890,723 (54.6)




47.1 (28.27) 52.8 (25.58) 48.1 (27.90)
Median
(Q1-Q3)





6.4 (12.34) 7.5 (8.79) 4.5 (6.08)
Median
(Q1-Q3)
3 (1–6) 5 (X†-9) 3 (2–5)
†For reasons of confidentiality, this number was blinded by the German
Federal Statistical Office.
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older, with a mean age of 52.8 years (standard deviation
25.58 years, median 59 years), and were hospitalized lon-
ger, with a mean length of 7.5 days (standard deviation
8.79 days, median 5 days). There were noticeable differ-
ences between England and the USA regarding the fre-
quencies of emergencies and operations. Thus, in the
USA, inpatients were operated on more frequently
(54.6% vs. 45.7%) and were less frequently admitted as
emergency cases (45.7% vs. 54.2%).
ADE prevalence
In the English HES, there were 142,845 inpatient stays
related to ADEs (2.3% of 6,202,313 inpatient stays). For
the German DRG statistic, there were 775,959 inpatient
stays involving an ADE (4.8% of 16,230,407 inpatients)Table 3 Standardized prevalence rates of ADEs for England, G
Category Definition
A Caused by a drug or other substance
B Poisoning by or harmful use of a drug or other substance
C ADE very likely
A-C
*Inpatient stays were counted once within each category. The rates were adjusted f
direct standardization: operation (yes/no), sex (male/female), emergency (yes/no), a
mean number of secondary diagnoses in Germany.
†Inpatients stays were counted twice in categories A and B if the ADE occurred in e
the initial results, which were differentiated according to principal and secondary d
multiplied by a factor of 0.88.while according to the USA's NIS 520,555 inpatient stays
involved an ADE (7.3% of 7,125,028 inpatient stays). The
adjusted prevalence rate of ADEs was highest for the
USA, with 5.64% [5.63–5.66%] followed by Germany
with 4.78% [4.73–4.83%] (cf. Table 3). England had the
lowest rate, with 3.22% [3.20–3.23%]. The rates in the
three categories (A, B, and C) were comparable for
Germany and the USA whereas in England the rate for
ADEs in category A was significantly lower than that of
either Germany or the USA: 0.99% [0.99–1.00%] vs.
3.14% [3.10–3.17%] and 4.43% [4.42–4.45%], respect-
ively, and the rate for category B was twice as high, with
1.21% [1.20–1.22%]. The most frequent ADE in all coun-
tries was enterocolitis due to Clostridium difficile (cat-
egory C), with 33,509 inpatients in England (23.5% of all
inpatients with an ADE, prevalence rate 0.54%), 36,215
inpatients in Germany (4.7% of all inpatients with an
ADE, prevalence rate 0.24%) [5], and 56,771 inpatients in
the USA (10.9% of all inpatients with an ADE, prevalence
rate 0.80%). The second most frequent ADE in Germany
and the USA was secondary thrombocytopenia (category
C). This was followed by drug poisoning (category B.1),
both in England (rank 2–5) and in the USA (rank 3–5).
The drugs specifically responsible were benzodiazepines,
antidepressants, and nonsteroidal anti-inflammatory drugs.
In Germany, drug-induced agranulocytosis and neutropenia
(category A.1) and drug-induced aplastic anemia due to
chemotherapy (category A.1) occupied positions 3 and 4
(cf. Table 4).
ADE associations
The odds ratios (ORs) for operation, sex, emergency, age
at admission, and length of stay are presented in Table 5.
In all countries, ADEs were associated with emergency
cases (ORs between 1.391 [1.384–1.397] and 8.082
[8.065–8.099]) and less associated with surgical treatment
(ORs between 0.367 [0.366–0.367] and 0.544 [0.543–
0.545]) and length of stay ≤ 10 days (ORs between 0.340
[0.339–0.341] and 0.418 [0.416–0.420]). In England and
Germany, ADEs were less associated with sex male
(ORs = 0.810 [0.809–0.812] and 0.894 [0.890–0.898])ermany and the USA
England* Germany† USA*
Rate in % [95% CI]
0.99 [0.99–1.00] 3.14 [3.10–3.17] 4.43 [4.42–4.45]
1.21 [1.20–1.22] 0.49 [0.48–0.51] 0.63 [0.63–0.64]
1.07 [1.07–1.08] 1.14 [1.11–1.16] 0.86 [0.85–0.87]
3.22 [3.20–3.23] 4.78 [4.73–4.83] 5.64 [5.63–5.66]
or the distribution of the following data elements in the DRG statistic using a
ge at admission (≤ 53 years/> 53 years). The rates were further adjusted for the
ach of the sub-categories. Otherwise, they were counted once. To aggregate
iagnoses, the total number of inpatient stays for categories A, B, and C was
Table 4 The five most frequent ADE codes in England, Germany and USA, in descending order
Code Title Category Number of inpatients
Germany†
A04.7 Enterocolitis due to Clostridium difficile C 36,215
D69.58 Other secondary thrombocytopenia, not classified as transfusion-refractory C 32,600
D70.10 Drug-induced agranulocytosis and neutropenia: critical phase < 10 days A.1 16,044
D61.10 Drug-induced aplastic anemia A.1 14,002
D69.59 Secondary thrombocytopenia not otherwise specified C 12,560
England
A04.7 Enterocolitis due to Clostridium difficile C 33,509
T39.1 Poisoning by 4-aminophenol derivatives B.1 27,208
T43.2 Poisoning by other and unspecified antidepressants B.1 8,231
T39.3 Poisoning by other nonsteroidal anti-inflammatory drug (NSAID) B.1 8,051
T42.4 Poisoning by benzodiazepines B.1 8,035
USA
008.45 Intestinal infection due to Clostridium difficile C 56,771
287.4 Secondary thrombocytopenia C 22,700
969.4 Poisoning by benzodiazepine-based tranquilizers B.1 12,683
969.0 Poisoning by antidepressants B.1 7,332
965.4 Poisoning by aromatic analgesics, not elsewhere classified B.1 5,119
†Translation from the German by the author.
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= 1.225 [1.222–1.227]. In Germany and the USA, ADEs
were less associated with age ≤ 53 years (ORs = 0.648
[0.645–0.651] and 0.842 [0.840–0.844]) whereas in Eng-




To our knowledge, this is the first study presenting a
transnational comparison of ADE rates based on routine
data. ADE frequencies were comparable in Germany and
the USA, with one out of 20 inpatients suffering an ADE
at the time of admission or during the hospital stay. Pa-
tients with ADEs were older, were admitted as emer-
gency cases, did not undergo any surgical procedure,
and had a longer hospital stay. The majority of the ADEs
could be identified by codes explicitly mentioning aTable 5 Odds ratios for ADEs in England, Germany, and the U
Variable England




Age≤ 53 years 1.076 [1.073–1.078]
Length of stay≤ 10 days 0.340 [0.339–0.341]
Confidence intervals are indicated in square brackets.drug. By contrast, the ADE prevalence rate in England
was remarkably lower, with poisoning or harmful use
coded more frequently than in Germany or the USA.
More than 80% of the patients in England were admitted
as emergencies. However, the five most frequent, very
likely ADEs were nearly identical in England and the
USA. Some of the differences between the three countries
examined in this study might have been due to variations
in documentation and coding. A report of the OECD
highlighted those variations in comparing several of the
characteristics of routine data for 19 countries. The mean
number of secondary diagnoses for denominator cases of
the AHRQ’s indicator “Foreign body left in during proced-
ure” varied between 1.50 (Italy) and 6.72 (Belgium) [10].
The numbers for the USA and Germany were, respect-
ively, 6.02 and 5.31 whereas in the UK the mean number
of secondary diagnoses was 2.72. However, this does not
explain the results of the current study, because theSA
Germany USA
0.894 [0.890–0.898] 1.225 [1.222–1.227]
1.391 [1.384–1.397] 2.336 [2.331–2.341]
0.591 [0.588–0.594] 0.544 [0.543–0.545]
0.648 [0.645–0.651] 0.842 [0.840–0.844]
0.376 [0.374–0.378] 0.418 [0.416–0.420]
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for those differences. In the OECD’s report, six of the 17
countries for which information was available used a vari-
ant of the ICD-9 for coding; the remaining 11 used a
variant of the ICD-10. Differences in the representation of
specific diseases have been reported anecdotally between
ICD-9 and ICD-10 but also between variants of ICD-10
[16]. Different code distributions for the five ADE categor-
ies of Germany’s ICD-10-GM and England’s ICD-10 and
the USA's ICD-9-CM suggest classification differences as a
possible reason for confounding, pointing out the value of
explicitly addressing ADEs in the development of ICD-11.
Comparison with the existing literature on ADE
frequencies in routine data
Three previous studies used HES data to analyze the
prevalence rate of ADEs [17-19]. Waller et al. reported a
stable rate of inpatients with an admission due to an ADE
of about 0.35% for the years 1996 to 2000 in England [18].
According to Patel et al., the prevalence rate for the years
1998 to 2005 was slightly higher, 0.50% [17]. Unlike the
present work, neither study analyzed the association of
ADEs with demographic or other characteristics. Waller
et al. selected inpatient stays (“admissions”) as the obser-
vational unit, and Patel et al. episodes. The difference
between the two studies might therefore have been due to
the inclusion by Patel et al. of ADEs occurring during the
hospital stay. In the third study, Wu et al. selected emer-
gency admissions between 1999 and 2009, using all
diagnoses in identifying ADEs and thus accepting ADEs
occurring at the time of admission as well as later on [19].
Linking episodes to admissions, those authors found an
overall prevalence rate for all years of 0.9% and a preva-
lence rate in the last year of their study (2009) of 1.1%. In
contrast to this study, none of those three studies consid-
ered codes not explicitly mentioning drugs. Excluding cat-
egory C from this study would have lowered the
calculated rate by one third. The remaining unadjusted
rate for England is within the published scope for HES
data, thus underlining the appropriateness of the method-
ology applied herein. Unfortunately, comparable analyses
for the USA, to the best of this author's knowledge, have
not been published.
In a nationwide study in The Netherlands, a prevalence
rate of 1.83% was reported for all acute non-planned in-
patient stays in 2001 [20]. Corresponding with the results
determined for Germany in the current study, patients
suffering an ADE were older and more often female and
had a longer mean length of stay (12.5 vs. 10 days). In an
Australian study based on discharges from three hospitals
over a period of three months in 2004 and applying the
external causes codes of the ICD-10 Australian Modifica-
tions (ICD-10-AM), an ADR prevalence rate of 4.5% was
reported [3]. This high prevalence rate likely reflectsthe comprehensive and well-established ADR reporting
system of the three hospitals, as the authors concluded
that “The ICD-10-AM coding surveillance is an effect-
ive and efficient method of improving ADR identifica-
tion and reporting”. However, they noted that carrying
out chart reviews of all marked cases was remarkably
time-consuming.
Differences in ADE frequencies between routine data and
prospective monitoring studies
The frequency of ADEs and ADRs in hospitals as re-
ported from prospective monitoring studies is higher
than that determined by analyses of routine data. For ex-
ample, in their meta-analysis of 39 studies Lazarou et al.
estimated an ADR prevalence rate for the USA of 15.1%
[21]. The studies analyzed by those authors reported a
prevalence rate of serious ADEs of 1.0–16.8% (estimate
6.7%), thus demonstrating a relevant uncertainty regard-
ing the “real” number. Indeed, one may ask whether
ADEs are seriously under-reported in routine data. How-
ever, false positives have to be considered as well.
Houghland et al. found that only 64.9% of ADEs indi-
cated by an ICD-9-CM code could be confirmed
through chart reviews [4]. Both under-reporting of ADEs
because they have been incompletely documented and
are therefore missing from routine data and over-
reporting of ADEs because of false positives have to be
taken into account. Alternatively, it may be the case that
the two balance each other out, leading to plausible esti-
mates. This latter notion is supported by evidence from
other adverse events [22,23]. For example, a similar fre-
quency of hospital-acquired pneumonia was determined
by chart review and routine data analysis [22]. With
chart review as the gold standard, routine data had a
sensitivity of 43% and a positive predictive value of 64%,
thereby equalizing an under- and an over-reporting. For
pressure ulcer, a sensitivity of 47% was calculated in a
comparison of routine data recorded in a quality man-
agement project with a cross-sectional validation survey
[24]. The extrapolated period prevalence rate of 2.3% de-
termined in the cross-sectional validation survey has to
be compared with the rate of 1.4% of pressure ulcers de-
tected through the analysis of routine data. In our study,
the calculated rates of ADEs for England, Germany, and
the USA were more similar than the ADE rates pub-
lished from prospective monitoring studies.
Study limitations
The routine data of England and the USA were adapted
to the German data in order to reach a conformance
level that excluded data quality issues, differences in
demographics, and differences in service structure as
possible confounders. In addition, NHS services uncom-
mon in Germany and the USA were excluded. While the
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adaptations may have introduced certain biases. Further
research is necessary to weigh the pros and cons of the
use of routine data in transnational health services re-
search. On the one hand, it would be interesting to com-
pare drug and medication safety during inpatient care,
accepting that there are differences in the service struc-
tures of different countries. Thus, it may be that differ-
ences in ADE frequency highlight the influence of these
different structures on ADE occurrence. On the other
hand, drug and medication safety alone, independent of
the service structure, may be of interest. In this case, a
method would be needed to homogenize the data related
to the service structure. Especially for England, the re-
sults presented here might not be representative of the
HES database in full, given the exclusion of inpatient
stays with a length of null days.
Differences in ADE frequencies arising from the differ-
ent coding processes in the three countries were not con-
sidered in this study. For example, in Germany coding is
often integrated into the clinical process whereas this
might not be the case in England and USA. However, cor-
rections for different levels of coding completeness may
well have compensated for those factors.
The German data were available through teleprocessing
only, which made the respective analysis much more diffi-
cult and resource-consuming than the direct use of raw
data. Consequently, the German DRG statistic formed the
basis of the transnational analysis. It was not feasible to
consider questions arising from the HES and NIS analyses.
Clearly, the mixture of classification revisions and national
classification variants is problematic in the identification
of ADEs using ICD codes. Thus, after mapping, there
were shifts between categories (e.g., from A.1 to A.2) that
occurred because of the slightly different denominations
of a similar code. The results became increasingly incom-
patible at deeper category levels. For this reason, the ADE
prevalence rates reported at the most detailed level were
excluded.
The NIS uses a specific sample of hospitals in the
USA [10], excluding, among others, the nationwide sys-
tem of Veterans Hospitals. Furthermore, there are state-
specific restrictions for the inclusion of inpatients or
data sources. Nevertheless, the huge number of inpa-
tients available in the NIS database should guarantee a
reliable estimate of the ADE frequency in the USA.
In this study, there was an intentional underestimate
of ADEs because of the focus on ICD codes with a close
relationship to the administration of a drug, one either
explicitly mentioned in the code or implicitly indicated
by the disease. However, the list of codes applied here is
the most complete one available [24]. In contrast to
other publications, this list includes diseases that are
pathognomonic for the administration of a drug, suchthat the ADE prevalence rate calculated from routine
data provides a realistic picture of the true frequency of
ADEs. ADEs of the type “need to add drug” and “un-
treated indication” were not included in the presented
analysis. According to a recent study of emergency de-
partment patients, ADEs of those types account for 15%
of all ADEs [25].
Conclusions
Routine data are among the several readily available re-
sources that can be used for health services research and
to answer pharmaco-epidemiological questions. Pharma-
covigilance based on spontaneous reporting by health
professionals is extremely incomplete [26,27]. If used as
trigger tool, routine data have the potential to achieve
completeness. The prerequisite is coding in parallel with
the inpatient stay. For the application in trigger tools
routine data do not only include diagnoses but also lab
values and other information [28]. However, from the
point of view of transnational health services research,
this is a goal for the remote future since it would first re-
quire an international standardization of terms beyond
the diagnosis codes. In the meantime, it might be worth-
while to reach a worldwide consensus on a set of charac-
teristics that should be provided in each publication on
ADE frequencies, independent of the type of data.
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